{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T08:22:30Z","timestamp":1781770950157,"version":"3.54.5"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T00:00:00Z","timestamp":1679529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T00:00:00Z","timestamp":1679529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To verify the long-term (24-week) efficacy, safety, and tolerability of fremanezumab in real-life patients with high-frequency episodic migraine (HFEM:\u2009\u2265\u20098\u00a0days\/month) or chronic migraine (CM:\u2009\u2265\u200915\u00a0days\/month), and multiple preventive treatment failures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a prospective, cohort, real-life study at 28 headache centers on consecutive patients affected by HFEM or CM with multiple preventive treatment failures who were prescribed subcutaneous fremanezumab (225\u00a0mg monthly\/675\u00a0mg quarterly) for\u2009\u2265\u200924\u00a0weeks. Primary endpoint was the change in monthly migraine days (MMDs) in HFEM and monthly headache days (MHDs) in CM at weeks 21\u201324 compared to baseline. Secondary endpoints encompassed changes in monthly analgesic medications,\u2009\u2265\u200950%,\u2009\u2265\u200975%, and 100% responder rates, and variation in NRS, HIT-6 and MIDAS scores at the same time interval. Changes in MMDs\/MHDs, monthly analgesic medications,\u2009\u2265\u200950%,\u2009\u2265\u200975%, and 100% responder rates, and variation in NRS and HIT-6 scores at week 4 were also monitored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Four hundred ten patients who had received\u2009\u2265\u20091 dose of fremanezumab were considered for safety analysis while 148 patients treated for\u2009\u2265\u200924\u00a0weeks were included in the efficacy analysis. At weeks 21\u201324, fremanezumab significantly (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) reduced MMDs, MHDs, monthly analgesic medications and NRS, HIT-6, and MIDAS scores in both HFEM and CM compared to baseline. The proportions of\u2009\u2265\u200950%,\u2009\u2265\u200975% and 100% responders at weeks 21-24were 75.0%, 30.8%, 9.6% (HFEM), and 72.9, 44.8 and 1% (CM). A significant (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) decrease in MMDs, MHDs, monthly analgesic medications and NRS, HIT-6, and MIDAS scores in both HFEM and CM was already present at week 4. The proportions of\u2009\u2265\u200950%,\u2009\u2265\u200975%, and 100% responders at week 4 were 67.6%, 32.4%, 11.8% (HFEM) and 67.3%, 40%, 1.8% (CM). CM remitted to episodic migraine and medication overuse to no-medication overuse in 83.3 and 75% of patients at week 24, and in 80 and 72.4% at week 4. Adverse events were rare (2.4%), mild and transient. No patient discontinued treatment for any reason.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Fremanezumab is characterized by an early and sustained efficacy in HFEM and CM patients with multiple preventive treatment failures in real-life, revealing an optimal safety and tolerability profile.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s10194-023-01561-w","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T20:03:37Z","timestamp":1679515417000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study"],"prefix":"10.1186","volume":"24","author":[{"given":"Piero","family":"Barbanti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Egeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Aurilia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Torelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Finocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florindo","family":"d\u2019Onofrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"d\u2019Onofrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Di Clemente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Ranieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Autunno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliano","family":"Sette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Carnevale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Aguggia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Tasillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Zoroddu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Frediani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Filippi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Tomino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Proietti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Bonassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the FRIEND-Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Albanese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Bertolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Bertuzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Bloise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Borrello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Camarda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Fiorentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Licia","family":"Grazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenica","family":"Le Pera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Querzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Salerno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Strumia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Valenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Vernieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Viticchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,23]]},"reference":[{"issue":"9","key":"1561_CR1","doi-asserted-by":"publisher","first-page":"5673","DOI":"10.1007\/s10072-022-06199-1","volume":"43","author":"D Mascarella","year":"2022","unstructured":"Mascarella D, Matteo E, Favoni V, Cevoli S (2022) The ultimate guide to the anti-CGRP monoclonal antibodies galaxy. Neurol Sci 43(9):5673\u20135685","journal-title":"Neurol Sci"},{"issue":"2","key":"1561_CR2","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/head.14032","volume":"61","author":"P Barbanti","year":"2021","unstructured":"Barbanti P, Aurilia C, Egeo G et al (2021) Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study. Headache 61(2):363\u2013372","journal-title":"Headache"},{"issue":"9","key":"1561_CR3","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1111\/head.14194","volume":"61","author":"P Barbanti","year":"2021","unstructured":"Barbanti P, Aurilia C, Cevoli S et al (2021) Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study. Headache 61(9):1351\u20131363","journal-title":"Headache"},{"issue":"1","key":"1561_CR4","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s10194-021-01247-1","volume":"22","author":"F Vernieri","year":"2021","unstructured":"Vernieri F, Altamura C, Brunelli N et al (2021) Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study). J Headache Pain 22(1):35","journal-title":"J Headache Pain"},{"key":"1561_CR5","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s10194-022-01498-6","volume":"23","author":"P Barbanti","year":"2022","unstructured":"Barbanti P, Egeo G, Aurilia C et al (2022) Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients. J Headache Pain 23:138. https:\/\/doi.org\/10.1186\/s10194-022-01498-6","journal-title":"J Headache Pain"},{"issue":"19","key":"1561_CR6","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1001\/jama.2018.4853","volume":"319","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, Silberstein SD, Bigal ME et al (2018) Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA 319(19):1999\u20132008","journal-title":"JAMA"},{"issue":"22","key":"1561_CR7","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","volume":"377","author":"SD Silberstein","year":"2017","unstructured":"Silberstein SD, Dodick DW, Bigal ME et al (2017) Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med 377(22):2113\u20132122","journal-title":"N Engl J Med"},{"issue":"10203","key":"1561_CR8","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","volume":"394","author":"MD Ferrari","year":"2019","unstructured":"Ferrari MD, Diener HC, Ning X et al (2019) Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet 394(10203):1030\u20131040","journal-title":"Lancet"},{"issue":"1","key":"1561_CR9","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s10194-022-01396-x","volume":"23","author":"P Barbanti","year":"2022","unstructured":"Barbanti P, Egeo G, Aurilia C et al (2022) Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study). J Headache Pain 23(1):46","journal-title":"J Headache Pain"},{"key":"1561_CR10","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1177\/0333102413485658","volume":"33","author":"Headache Classification Committee of the International Headache Society","year":"2013","unstructured":"Headache Classification Committee of the International Headache Society (2013) The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 33:629\u2013808","journal-title":"Cephalalgia"},{"key":"1561_CR11","unstructured":"Gazzetta Ufficiale n.182, 21\u20137\u20132020. https:\/\/www.gazzettaufficiale.it\/gazzetta\/serie_generale\/caricaDettaglio?dataPubblicazioneGazzetta=2020-07-21&numeroGazzetta=182"},{"issue":"1","key":"1561_CR12","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s10194-021-01279-7","volume":"22","author":"M Ashina","year":"2021","unstructured":"Ashina M, Cohen JM, Galic M et al (2021) Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study. J Headache Pain 22(1):68","journal-title":"J Headache Pain"},{"issue":"Suppl 1","key":"1561_CR13","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s10072-019-03839-x","volume":"40","author":"P Barbanti","year":"2019","unstructured":"Barbanti P, Aurilia C, Egeo G, Fofi L (2019) Erenumab: from scientific evidence to clinical practice-the first Italian real-life data. Neurol Sci 40(Suppl 1):177\u2013179","journal-title":"Neurol Sci"},{"issue":"2","key":"1561_CR14","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/head.14032","volume":"61","author":"P Barbanti","year":"2021","unstructured":"Barbanti P, Aurilia C, Egeo G et al (2021) Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study. Headache 61(2):363\u2013372","journal-title":"Headache"},{"issue":"4","key":"1561_CR15","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1111\/ene.15197","volume":"29","author":"F Vernieri","year":"2022","unstructured":"Vernieri F, Altamura C, Brunelli N et al (2022) Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3-month observational, longitudinal, cohort, multicenter. Italian real-life study Eur J Neurol 29(4):1198\u20131208","journal-title":"Italian real-life study Eur J Neurol"},{"key":"1561_CR16","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15563","author":"F Vernieri","year":"2022","unstructured":"Vernieri F, Brunelli N, Marcosano M et al (2022) Maintenance of response and predictive factors of 1-year Galcanezum Ab treatment in real-life migraine patients in Italy: The multicenter prospective cohort GARLIT study. Eur J Neurol. https:\/\/doi.org\/10.1111\/ene.15563","journal-title":"Eur J Neurol"},{"issue":"1","key":"1561_CR17","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s10194-022-01396-x","volume":"23","author":"P Barbanti","year":"2022","unstructured":"Barbanti P, Egeo G, Aurilia C et al (2022) Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study). J Headache Pain 23(1):46","journal-title":"J Headache Pain"},{"issue":"14","key":"1561_CR18","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1212\/WNL.0b013e3182a6cb72","volume":"81","author":"E Cernuda-Moroll\u00f3n","year":"2013","unstructured":"Cernuda-Moroll\u00f3n E, Larrosa D, Ram\u00f3n C et al (2013) Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. Neurology 81(14):1191\u20131196","journal-title":"Neurology"},{"issue":"2","key":"1561_CR19","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/0304-3940(94)90782-X","volume":"182","author":"AA Mathe","year":"1994","unstructured":"Mathe AA, Agren H, Lindstrom L, Theodorsson E (1994) Increased concentration of calcitonin gene-relatedpeptide in cerebrospinal fluid of depressed patients. A possible trait marker of major depressive disorder. Neurosci Lett 182(2):138\u2013142","journal-title":"Neurosci Lett"},{"issue":"12","key":"1561_CR20","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.3390\/pharmaceutics12121180","volume":"12","author":"D Szkutnik-Fiedler","year":"2020","unstructured":"Szkutnik-Fiedler D (2020) Pharmacokinetics, Pharmacodynamics and Drug-Drug Interactions of New Anti-Migraine Drugs-Lasmiditan, Gepants, and Calcitonin-Gene-Related Peptide (CGRP) Receptor Monoclonal Antibodies. Pharmaceutics 12(12):1180. https:\/\/doi.org\/10.3390\/pharmaceutics12121180","journal-title":"Pharmaceutics"},{"issue":"22","key":"1561_CR21","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","volume":"377","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, Reuter U, Hallstr\u00f6m Y et al (2017) A controlled trial of Erenumab for episodic migraine. N Engl J Med 377(22):2123\u20132132","journal-title":"N Engl J Med"},{"issue":"6","key":"1561_CR22","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","volume":"16","author":"S Tepper","year":"2017","unstructured":"Tepper S, Ashina M, Reuter U et al (2017) Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 16(6):425\u2013434","journal-title":"Lancet Neurol"},{"issue":"10161","key":"1561_CR23","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1016\/S0140-6736(18)32534-0","volume":"392","author":"U Reuter","year":"2018","unstructured":"Reuter U, Goadsby PJ, Lanteri-Minet M et al (2018) Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet 392(10161):2280\u20132287","journal-title":"Lancet"},{"issue":"9","key":"1561_CR24","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","volume":"75","author":"VL Stauffer","year":"2018","unstructured":"Stauffer VL, Dodick DW, Zhang Q et al (2018) Evaluation of Galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol 75(9):1080\u20131088","journal-title":"JAMA Neurol"},{"issue":"8","key":"1561_CR25","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1177\/0333102418779543","volume":"38","author":"V Skljarevski","year":"2018","unstructured":"Skljarevski V, Matharu M, Millen BA et al (2018) Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia 38(8):1442\u20131454","journal-title":"Cephalalgia"},{"issue":"10","key":"1561_CR26","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/S1474-4422(20)30279-9","volume":"19","author":"WM Mulleners","year":"2020","unstructured":"Mulleners WM, Kim BK, L\u00e1inez MJA et al (2020) Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol 19(10):814\u2013825","journal-title":"Lancet Neurol"},{"issue":"13","key":"1561_CR27","doi-asserted-by":"publisher","first-page":"e1365","DOI":"10.1212\/WNL.0000000000009169","volume":"94","author":"RB Lipton","year":"2020","unstructured":"Lipton RB, Goadsby PJ, Smith J et al (2020) Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology 94(13):e1365\u2013e1377","journal-title":"Neurology"},{"issue":"3","key":"1561_CR28","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/0333102420905132","volume":"40","author":"M Ashina","year":"2020","unstructured":"Ashina M, Saper J, Cady R et al (2020) Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia 40(3):241\u2013254","journal-title":"Cephalalgia"},{"issue":"7","key":"1561_CR29","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S1474-4422(22)00185-5","volume":"21","author":"M Ashina","year":"2022","unstructured":"Ashina M, Lanteri-Minet M, Pozo-Rosich P et al (2022) Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol 21(7):597\u2013607","journal-title":"Lancet Neurol"},{"issue":"23","key":"1561_CR30","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1001\/jama.2021.7665","volume":"325","author":"PK Winner","year":"2021","unstructured":"Winner PK, McAllister P, Chakhava G et al (2021) Effects of intravenous Eptinezumab vs placebo on headache pain and most bothersome symptom when initiated during a migraine attack: a randomized clinical trial. JAMA 325(23):2348\u20132356","journal-title":"JAMA"},{"issue":"13","key":"1561_CR31","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1177\/0333102418771376","volume":"38","author":"O Cohen-Barak","year":"2018","unstructured":"Cohen-Barak O, Weiss S, Rasamoelisolo M et al (2018) A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjects. Cephalalgia 38(13):1960\u20131971","journal-title":"Cephalalgia"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-023-01561-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-023-01561-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-023-01561-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T20:03:40Z","timestamp":1679515420000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-023-01561-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,23]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1561"],"URL":"https:\/\/doi.org\/10.1186\/s10194-023-01561-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2485476\/v1","asserted-by":"object"}]},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,23]]},"assertion":[{"value":"16 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients provided written informed consent. The study was approved by IRCCS San Raffaele Rome Ethical Committee n RP 19\/26, mutually recognized by the other local ethical committees.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Piero Barbanti received travel grants, honoraria for advisory boards, speaker panels or clinical investigation studies from Alder, Allergan, Angelini, Assosalute, Bayer, ElectroCore, Eli-Lilly, GSK, Lundbeck, Lusofarmaco, 1MED, MSD, New Penta, Noema Pharma, Novartis, Stx-Med, Teva, Visufarma, Zambon.CinziaAurilia received travel grants from FB-Health, Lusofarmaco, Almirall, Eli-Lilly Novartis and Teva;Gabriella Egeo received travel grants and honoraria from Eli-Lilly, Novartis, New Penta and Ecupharma;Paola Torelli received travel grants and honoraria from Allergan, Teva, Eli-Lilly and Novartis.Cinzia Finocchi received grants and honoraria from Novartis, Eli Lilly, TEVA, AIM group.Florindo d'Onofrio received travel grant, honoraria as a speaker or for partecipating in advisory boards from Novartis, Teva, Neopharmed Gentili, Qbgroupsrl, K link srl and Eli-Lilly.Luigi d\u2019Onofrio has no disclosures to declaire.Renata Rao received honoraria for speaker panels from Teva, Lilly, Novartis, Allergan, Lundbeck.Stefano Messina has no disclosures to declare.Laura Di Clemente has no disclosures to declare.Angelo Ranieri received speaker honoraria from Teva, Lilly.Massimo Autunno has no disclosures to declare.Giuliano Sette has no disclosures to declare.Bruno Colombohas received congress fee reimbursements from Teva and Novartis.Antonio Carnevalehas no disclosures to declare.Marco Aguggia received grants from Novartis and Lilly.Miriam Tasillo has no disclosures to declare.Francesco Zoredduhas no disclosures to declare.Fabio Frediani has received fees for participation on advisory boards, speaker honoraria or consulting activities from Angelini, Cristalfarma, Ecupharma, IBSA, Lundbeck, Novartis, PIAM, Teva.Massimo Filippi is Editor-in-Chief of the Journal of Neurology; received compensation for consulting services and\/or speaking activities from Bayer, Biogen Idec, Merck-Serono, Novartis, Roche, Sanofi Genzyme, Takeda, and Teva Pharmaceutical Industries; and receives research support from Biogen Idec, Merck-Serono, Novartis, Roche, Teva Pharmaceutical Industries, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla, and ARiSLA (Fondazione Italiana di Ricerca per la SLA).C. Tomino has no disclosures to declare.S. Proiettihas no disclosures to declare.S. Bonassi has no disclosures to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"30"}}